Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that attack ...
Many patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma do not undergo immunoglobulin G testing despite its potential to reduce likelihood of severe infections. Blood cancers increase ...
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...
On Monday, Biohaven Ltd. BHVN revealed clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE) platform and its glutamate modulation and ion ...
BHV-1300 reduced total IgG by up to 84% in a four-week Phase 1 study. The treatment was well-tolerated, with no serious adverse events reported. Get access to the leaderboards pointing to tomorrow’s ...
In early-onset severe hemolytic disease of the fetus and newborn (HDFN), transplacental transfer of maternal antierythrocyte IgG alloantibodies causes fetal anemia that leads to the use of high-risk ...
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback